Gene Techno Science Enters into Research Agreement with Nagoya University
March 06, 2020
Share
Gene Techno Science Co. Ltd. has executed a joint research agreement with Nagoya University, for a development of new therapy for spinal cord injury. Department of Neurosurgery in Nagoya University Hospital has a surgery record in various spinal cord diseases including spinal cord injury. In addition, it has strenuously advanced basic research on the neuronal regeneration and achieved significant research results. GTS and Nagoya University agreed on the potential utility of SHED for a new therapy of spinal cord injury, resulting in this joint research agreement. Deal Status completed on March 05. 2020.
Kidswell Bio Corp, formerly Gene Techno Science Co Ltd, is a Japan-based company mainly engaged in the development of biopharmaceuticals. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.
KIDSWELL BIO CORPORATION 
